



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number	10/538,370
Filing Date	June 13, 2005
First Named Inventor	EMTAGE, Peter C.R.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	HYS-67PCT/US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Form PTO 1449 Copies of 23 References Return Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	NUVELO, Inc.		
Signature			
Printed name	Renee S. Polizotto		
Date	September 9, 2005	Reg. No.	53,474

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Steven C. Garland	Date	September 9, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



JC06 Rec'd PCT/PTO 12 SEP 2005
PATENT
Docket No.: HYS-67PCT/US

P C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Peter C.R. Emtage
Serial No: 10/538,370
Filed: June 13, 2005
For: METHODS OF THERAPY AND
DIAGNOSIS USING
TARGETING OF CELLS THAT
EXPRESS LAX

CERTIFICATE OF MAILING
UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, with sufficient postage as first class mail in an envelope addressed to Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: September 9, 2005

Type or Print Name of Person Mailing: Steven C. Garland

Signature of Person Mailing

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached form PTO-1449 is hereby submitted by Applicants in connection with the above-identified application. Pursuant to 37 C.F.R. §1.98(d), copies of the documents C1-C23 cited on the PTO-1449 submitted herewith.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 U.S.C. § 102 or § 103.

In accordance with 37 C.F.R. §1.98(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and the Examiner is respectfully requested to consider the listed references.

PATENT
Docket No.: HYS-67PCT/US

No fee is believed due under 37 C.F.R. §1.97(b) because this statement and Form PTO-1449 are being submitted within three months of filing the above-identified patent application. However, the Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 501169.

Respectfully submitted,

Date: September 9, 2005

By: Renee S. Polizotto
Renee S. Polizotto, Ph.D.
Agent for Applicants
Reg. No. 53,474
Customer No. 34285
Nuvelo, Inc..
675 Almanor Avenue
Sunnyvale, CA 94085
Tel.: (408) 215.4000
Fax: (408) 524.8145



SHEET 1 of 3

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. HYS-67PCT/US	Serial No. 10/538,370
INFORMATION DISCLOSURE STATEMENT		Applicant Peter C.R. Emtage	
		Filing Date June 13, 2005	Group TBD
(Use several sheets if necessary)			

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclas s	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclas s	Translation
							Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C1	AMLOT <i>et al.</i> , "A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of a B-cell lymphoma resistant to conventional therapy," <i>Blood</i> 82(9):2624-2633 (1993).
	C2	ANDREAKOS <i>et al.</i> , "Monoclonal antibodies in immune and inflammatory diseases," <i>Curr. Opin. Biotechnol.</i> 13:615-620 (2002).
	C3	BERGER <i>et al.</i> , "Therapeutic applications of monoclonal antibodies," <i>Am. J. Med. Sci.</i> 324(21):14-30 (2002).
	C4	BIRNBAUM <i>et al.</i> , "Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts," <i>J. Endocrinol.</i> 141:535-540 (1994).
	C5	CRETICOS, "The consideration of immunotherapy in the treatment of allergic asthma," <i>Ann. Allergy Asthma Immunol.</i> 87(Suppl):13-27 (2001).
	C6	DAEMON <i>et al.</i> , "Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation," <i>Endocrinology</i> 139:3456-3464 (1998).

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. HYS-67PCT/US	Serial No. 10/538,370
INFORMATION DISCLOSURE STATEMENT		Applicant Peter C.R. Emtage	
		Filing Date June 13, 2005	Group TBD
(Use several sheets if necessary)			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C7	FONG, "Immunotherapy in autoimmune diseases," <i>Ann. Acad. Med. Singapore</i> 31:702-706 (2002).	
C8	HOFMANN and STOFFEL, "A database of membrane spanning protein segments," <i>Biol. Chem. Hoppe-Seyler</i> 374:166 (1993).	
C9	HORNICK <i>et al.</i> , "Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties," <i>Blood</i> 89(12):4437-4447 (1997).	
C10	HSU <i>et al.</i> , "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," <i>Nat. Med.</i> 2(1):52-58 (1996).	
C11	HSU <i>et al.</i> , "Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial," <i>Blood</i> 9(1):3129-3135 (1997).	
C12	JIANG <i>et al.</i> , " <i>In vitro</i> effects of HgCl ₂ on murine lymphocytes. I: Preferable activation of CD4 ⁺ T cells in a responder strain," <i>J. Immunol.</i> 154:3138-3146 (1995).	
C13	MALONEY <i>et al.</i> , "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDE-C2B8) in patients with recurrent B-cell lymphoma," <i>Blood</i> 84(8):2457-2466 (1994).	
C14	MALONEY <i>et al.</i> , "The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines," <i>Blood</i> 88(Suppl):637a (1996).	
C15	MALONEY <i>et al.</i> , "IDE-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma," <i>Blood</i> 90(6):2188-2195 (1997).	
C16	MARTIN <i>et al.</i> , "CD84 functions as a homophilic adhesion molecule and enhances IFN- γ secretion: adhesion is mediated by Ig-like domain 1," <i>J. Immunol.</i> 167:3668-3676 (2001).	
C17	OZAKI <i>et al.</i> , "Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24" <i>Blood</i> 90(8):3179-3186 (1997).	
C18	PRESS <i>et al.</i> , "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphoma," <i>Blood</i> 69(2):584-591 (1987).	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. HYS-67PCT/US	Serial No. 10/538,370
INFORMATION DISCLOSURE STATEMENT		Applicant Peter C.R. Emtage	
		Filing Date June 13, 2005	Group TBD
(Use several sheets if necessary)			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C19	REHWALD <i>et al.</i> , "Treatment of relapsed CD20 ⁺ Hodgkin's lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin lymphoma study group," <i>Blood</i> 101(2):420-424 (2003).	
C20	SIMPSON <i>et al.</i> , "Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR," <i>Molec. Vision</i> 6:178-183 (2000).	
C21	SINGH <i>et al.</i> , "The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma," <i>Vaccine</i> 20:1400-1411 (2002).	
C22	SPRENGER <i>et al.</i> , "Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer," <i>Cancer Res.</i> 59:2370-2375 (1999).	
C23	ZHU <i>et al.</i> , "Molecular cloning of a novel gene encoding a membrane associated adaptor protein (LAX) in lymphocyte signaling," <i>J. Biol. Chem.</i> 277(48):46151-46158 (2002).	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	